Loading...
•
Jun 30, 2022
LifeStance Q2 2022 Earnings Report
LifeStance reported solid results, with revenue growth driven by an increase in total clinicians. Profitability remained consistent with expectations.
Key Takeaways
LifeStance Health Group reported a 31% increase in revenue to $209.5 million. The company's net loss was $68.7 million, and Adjusted EBITDA was $14.6 million. The company is expecting full year 2022 revenue and Center Margin toward the bottom end of the previously guided ranges of $865 million to $885 million and $240 million to $255 million, respectively, due to refined clinician seasonality assumptions; reaffirming Adjusted EBITDA guidance of $63 million to $67 million.
Revenue increased by 31% to $209.5 million compared to the prior year.
Total clinicians increased by 31% to 5,226, a net increase of 237 in the second quarter.
Net loss was $68.7 million, impacted by stock-based compensation expense.
Adjusted EBITDA was $14.6 million, remaining relatively flat compared to the prior year.
LifeStance
LifeStance
Forward Guidance
LifeStance now expects full year 2022 revenue and Center Margin toward the bottom end of the previously guided ranges of $865 million to $885 million and $240 million to $255 million, respectively. LifeStance is reaffirming full year 2022 Adjusted EBITDA guidance of $63 million to $67 million. For the third quarter of 2022, the company expects revenue of $216 million to $221 million, Center Margin of $61 million to $65 million, and Adjusted EBITDA of $16 million to $19 million.